Arc Bio has launched the Galileo Pathogen Solution product line and first product, GPS-Transplant, a research-use-only next-generation sequencing test to aid in monitoring post-transplant patients for viral infections. GPS-Transplant detects the most common viral infections among transplant patients, including cytomegalovirus, Epstein–Barr virus, BK virus, and human adenovirus. The test also detects different variances and genotypes of the viruses, as well as more rare infections. GPS-Transplant also offers the ability to detect antiviral resistance mutations, and performs simultaneous quantitative detection of more than 350 viral strains. It is a sample-to-report solution built around the Illumina NGS platform that consists of reagents, built-in assay controls, and Galileo Analytics, a cloud-based proprietary software that provides quick and reliable results, an intuitive user interface, and detailed, actionable reports. The analytics software leverages Arc Bio's curated pathogen database called ArcIve, and also incorporates AMR resistance prediction technology which Arc Bio launched last year.